Biotechnology & Medical Research

Page 2

Regulus Therapeutics Inc receives orphan drug designation for RG-012

Monday, 21 Jul 2014 08:00am EDT

Regulus Therapeutics Inc:U.S. FDA granted orphan drug designation to RG-012.RG-012, a single stranded, chemically modified oligonucleotide that binds to and inhibits the function of microRNA-21, as a therapeutic for the treatment of Alport syndrome, a life-threatening genetic kidney disease with no approved therapy.In near term, Regulus expects to initiate natural history of disease study to gather further information about progression of Alport syndrome and to inform future clinical development plans of RG-012, key program under Regulus' 'Clinical Map Initiative.

Ignyta Inc announces initiation of STARTRK-1 global phase I/II clinical trial of RXDX-101

Monday, 21 Jul 2014 07:00am EDT

Ignyta Inc:Announces multicenter initiation of the company's global Phase I/II clinical trial of RXDX-101, its proprietary oral tyrosine kinase inhibitor targeting multiple solid tumor indications.This clinical trial is called STARTRK-1, which stands for StudyTargetingALK,ROS1 orTRKA/B/C, and is Phase I/IIa, multicenter, single-arm.Says open-label clinical trial of continuous daily dosing of oral RXDX-101 in adult patients with locally advanced or metastatic cancer confirmed to be positive for relevant molecular alterations.Trial will involve multiple clinical sites in the U.S., Europe, and Asia.Sites that Ignyta anticipates will dose patients in Phase I portion of trial include Chao Family Comprehensive Cancer Center at UC Irvine, Lombardi Comprehensive Cancer Center at Georgetown and.It also includes Massachusetts General Hospital/Dana Farber Cancer Institute, Memorial Sloan Kettering Cancer Center, Sarah Cannon Research Institute, and the University of Texas M.D. Anderson Cancer Center.

Tobira Therapeutics Inc sees IPO price between $12.00 and $14.00 per share - Form S-1/A

Monday, 21 Jul 2014 06:17am EDT

Tobira Therapeutics Inc:Offers 4,615,385 shares of its common stock.Anticipate that the initial public offering price of common stock will be between $12.00 and $14.00 per share.Says have applied to list common stock on The NASDAQ Global Market under the symbol TBRA.Intend to use the net proceeds to fund further development of CVC for the treatment of NASH, as well as for manufacturing of clinical drug supply, working capital and general corporate purposes.BMO Capital Markets Corp. and JMP Securities LLC are the representatives of the underwriters.Underwriters are BMO Capital Markets Corp, JMP Securities LLC, Oppenheimer & Co. Inc and Nomura Securities International, Inc.

Sunzen Biotech Bhd appoints Chief Executive Officer

Sunday, 20 Jul 2014 08:00pm EDT

Sunzen Biotech Bhd:Appointed Hong Choon Hau as Chief Executive Officer.Previously he was Non-Executive Director.

Sunzen Biotech Bhd announces Chairman & Managing Director resignation

Sunday, 20 Jul 2014 08:00pm EDT

Sunzen Biotech Bhd:Says Tan Kim Sing resigned from his post as Chairman & Managing Director.

StemCells Inc announces closing of $20 mln offering

Friday, 18 Jul 2014 01:40pm EDT

StemCells Inc:Announced that it has closed its previously announced offering of common stock and short term warrants.Says it sold a total of 11,299,435 units to two well recognized institutional biotechnology investors and received total proceeds, net of offering expenses and placement agent fees, of about $18.7 million.Each unit consists of one share of common stock and a warrant to purchase 0.85 of a share of common stock at a price of $1.77 per unit.Warrants will first be exercisable six months from the date of issuance at an initial exercise price of $2.17 per share.Warrants will expire at the close of business on Aug. 17, 2015.Ascendiant Capital Markets, LLC acted as financial advisor and placement agent for the offering.

4d Pharma PLC announces acquisition of The Microbiota Company Limited

Friday, 18 Jul 2014 02:00am EDT

4d Pharma PLC:Says that it has acquired the entire issued share capital of The Microbiota Company Limited, for a consideration of about 0.96 million pounds (equivalent to 1.2 million euros).Says which, together with the effective assumption of the obligations of a Loan gives an effective total consideration of 2.04 million pounds (equivalent to 2.55 million euros).Says the 0.96 million pound (equivalent to 1.2 million euros) consideration for the Acquisition was satisfied by the issue of 509,285 new ordinary shares in the capital of 4d pharma, with each 4d pharma Share being issued at 1.885 pounds.

Morphosys AG receives additional patents on novel antibody platform Ylanthia in the U.S. and first patent in China

Friday, 18 Jul 2014 01:31am EDT

Morphosys AG:Announces that the U.S. Patent and Trademark Office (USPTO) and the State Intellectual Property Office of China have granted additional patents covering the company's latest antibody platform Ylanthia.

Sage Therapeutics, Inc announces pricing of initial public offering

Thursday, 17 Jul 2014 06:54pm EDT

Sage Therapeutics, Inc:Announced the pricing of its initial public offering of 5,000,000 shares of common stock at a public offering price of $18.00 per share, before underwriting discounts.Says all of the common stock is being offered by SAGE.Says in addition, SAGE has granted the underwriters a 30-day option to purchase up to an additional 750,000 shares of common stock from SAGE at the public offering price to cover over-allotments, if any.Says the company's shares are expected to begin trading on the NASDAQ Global Market on July 18, 2014 under the ticker symbol SAGE.Says J.P. Morgan Securities LLC and Goldman, Sachs & Co. are acting as joint book-running managers.Says Leerink Partners LLC is acting as lead manager and Canaccord Genuity Inc. is acting as co-manager.

InterMune receives FDA breakthough therapy designation for pirfenidone

Thursday, 17 Jul 2014 12:38pm EDT

InterMune Inc:Says that pirfenidone has been granted Breakthough Therapy Designation from the U.S. Food and Drug Administration (FDA).This designation is reserved for drugs that are intended to treat a serious or life threatening disease or condition and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically endpoints.


  • Sectors
  • U.S.
  • Europe
  • Asia

Sector Summary

Analyst Research

Report Title Price
Provider: Edison Investment Research
Provider: Edison Investment Research
Provider: Edison Investment Research
Provider: Edison Investment Research
Provider: Edison Investment Research

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.